Avingtrans Plc (LON:AVG) has entered the new financial year with record revenue of £163m, adjusted EBITDA above £20m and more than 90% order coverage already secured. CEO Steve McQuillan explains what is driving the stronger margins, why nuclear life extension and new-build opportunities are gathering momentum, and how the Michigan expansion supports the next phase of growth. He also discusses Adaptix following its FDA 510(k) clearance and CE marking, the growing aerospace non-destructive testing pipeline and why the medical imaging business could now be approaching a breakthrough year for commercial sales.
Key Moments
- 00:14 – Record results — £163m revenue, £20m-plus EBITDA and EPS up 30%
- 00:46 – Order book visibility — Over 90% covered this year and around 50% already secured for next year
- 01:08 – Margins strengthen — Higher aftermarket sales and reduced medical losses lift profitability
- 01:48 – Nuclear demand accelerates — Life extension and new-build opportunities drive orders
- 02:55 – Adaptix clears key hurdles — FDA and CE approvals open the way for orthopaedic sales
- 03:31 – Aerospace pipeline builds — 3D X-ray technology targets opportunities conventional imaging can miss
- 04:24 – The next growth catalysts — Adaptix commercialisation, nuclear expansion and small modular reactors
Avingtrans plc is an international precision engineering group operating in highly regulated energy, infrastructure, medical and industrial imaging markets. Its Advanced Engineering Systems division supplies mission-critical engineered products and aftermarket services, with a growing focus on nuclear life extension, decommissioning and next-generation nuclear, while its Medical and Industrial Imaging division develops technologies including compact MRI and 3D X-ray systems through businesses such as Magnetica and Adaptix.
